Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002321584 | SCV002608516 | likely pathogenic | Familial thoracic aortic aneurysm and aortic dissection | 2017-04-17 | criteria provided, single submitter | clinical testing | The p.G1056D variant (also known as c.3167G>A), located in coding exon 43 of the COL3A1 gene, results from a G to A substitution at nucleotide position 3167. The glycine at codon 1056 is replaced by aspartic acid, an amino acid with similar properties. The majority (approximately two-thirds) of COL3A1 mutations identified to date have involved the substitution of another amino acid for glycine within the triple-helical domain (Pepin MG et al. Genet Med. 2014;16(12):881-8; Frank M et al. Eur J Hum Genet. 2015;23(12):1657-64). This particular glycine variant has been reported in a vascular Ehlers-Danlos syndrome (vEDS) cohort with limited clinical data as well as in a patient presenting with vEDS and neurological symptoms (Ananth AL et al. Semin Pediatr Neurol. 2014;21:77-81; Pepin MG et al. Genet. Med. 2014;16:881-8). Cultured dermal fibroblasts from one of these heterozygous individuals synthesized abnormal type III procollagen molecules (Ananth AL et al. Semin Pediatr Neurol. 2014;21:77-81). Internal structural analysis has demonstrated that this alteration disrupts the characteristic G-X-Y motif in the COL3A1 protein and inserts a bulky side chain into a sterically-constrained region (Bella J et al. Science. 1994;266:75-81; Hohenester E et al. Proc. Natl. Acad. Sci. U.S.A. 2008;105:18273-7). An amino acid substitution at the same codon, p.G1056S, has also been associated with vEDS (Pepin MG et al. Genet. Med. 2014;16:881-8). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Collagen Diagnostic Laboratory, |
RCV000087481 | SCV000120368 | pathogenic | Ehlers-Danlos syndrome, type 4 | no assertion criteria provided | clinical testing |